%PDF-1.4
%
79 0 obj
<>
endobj
76 0 obj
<>
endobj
150 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-11-07T16:06:26Z
2024-03-28T22:21:40-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T22:21:40-07:00
application/pdf
Heather
2002-756.dec
uuid:752926f9-1dd2-11b2-0a00-0f09278d5b00
uuid:752926fb-1dd2-11b2-0a00-1e0000000000
endstream
endobj
65 0 obj
<>
endobj
66 0 obj
<>
endobj
80 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 47 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 49 0 R/Type/Page>>
endobj
9 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 51 0 R/Type/Page>>
endobj
17 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 53 0 R/Type/Page>>
endobj
25 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 55 0 R/Type/Page>>
endobj
33 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 57 0 R/Type/Page>>
endobj
41 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 59 0 R/Type/Page>>
endobj
176 0 obj
[181 0 R]
endobj
177 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 1 K
/GS1 gs
54 54 m
558 54 l
S
BT
0 0 0 1 k
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 420.3613 35.9844 Tm
(The Journal of Rheumatology 2003; 30:12)Tj
0 Tc 0 Tw -45.7952 -0.0313 Td
(2546)Tj
ET
0 0 0 0 k
/GS0 gs
109.25 59.1 396.47 -10.84 re
f*
0.5 w
109.25 59.1 396.47 -10.84 re
S
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 74.4 714.5293 Tm
(Inflammation-induced expression of sialyl Lewis X-containing)Tj
0 -1.25 TD
(glycan on alpha 1-acid glycoprotein \(orosomucoid\) in human sera.)Tj
0 Tc T*
(J Exp Med 1993;177:657-66.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(10.)-875 (V)111 (an Dijk )18 (W)92 (, Brinkman-van der Linden ECM, Havenaar EC.)]TJ
2.175 -1.25 Td
(Glycosylation of alpha 1-acid glycoprotein \(orosomucoid\) in health)Tj
T*
(and disease: Occurrence, regulation, and possible functional )Tj
T*
[(implications. )18 (T)35 (rends Glycosci Glycotechnol \(TIGG\) )]TJ
0 Tc 0 Tw T*
(1998;10:235-45.)Tj
-0.00011 Tc 0.02499 Tw -2.1381 -1.25 Td
[(1)37 (1.)-875 (Poland DC, Schalkwijk CG, Stehouwer CD, Koeleman CA, van het)]TJ
2.1381 -1.25 Td
[(Hof B, van Dijk )18 (W)92 (. Increased alpha 3-fucosylation of alpha 1-acid)]TJ
T*
[(glycoprotein in )18 (T)70 (ype I diabetic patients is related to vascular )]TJ
T*
(function. Glycoconj J 2001;18:261-8.)Tj
-2.175 -1.25 Td
[(12.)-875 (Bond )55 (A, Kerr MA, Hay FC. Distinct oligosaccharide content of)]TJ
2.175 -1.25 Td
[(rheumatoid arthritis-derived immune complexes. )55 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1995;38:744-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(13.)-875 (Soltys )55 (AJ, Bond )55 (A, )18 (W)80 (estwood OM, Hay FC. )18 (The ef)18 (fects of altered)]TJ
2.175 -1.25 Td
[(glycosylation of IgG on rheumatoid factor)20 (-binding and immune)]TJ
0 Tc T*
[(complex formation. )55 (Adv Exp Med Biol 1995;376:155-60.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(14.)-875 (Malhotra R, )18 (W)80 (ormald MR, Rudd PM, Fischer PB, Dwek RA, Sim)]TJ
2.175 -1.25 Td
(RB. Glycosylation changes of IgG associated with rheumatoid)Tj
T*
(arthritis can activate complement via the mannose-binding protein.)Tj
T*
(Nature Medicine 1995;1:237-43.)Tj
-2.175 -1.25 Td
[(15.)-875 (Garred P)111 (, Madsen HO, Marquart H, et al. )18 (T)70 (wo edged role of)]TJ
2.175 -1.25 Td
(mannose binding lectin in rheumatoid arthritis: a cross sectional)Tj
T*
[(study)65 (. J Rheumatol 2000;27:26-34.)]TJ
-2.175 -1.25 Td
[(16.)-875 (Axford JS. Glycosylation and rheumatic disease. Biochim Biophys)]TJ
2.175 -1.25 Td
(Acta 1999;1455:219-29.)Tj
-2.175 -1.25 Td
[(17.)-875 (Axford J. )18 (The impact of glycobiology on medicine. )18 (T)35 (rends)]TJ
2.175 -1.25 Td
(Immunol 2001;22:237-9.)Tj
-2.175 -1.25 Td
[(18.)-875 (Pool )55 (AJ, )55 (Axford JS, )55 (Alavi )55 (A. Unique serum beta 1.4 galactosyl-)]TJ
2.175 -1.25 Td
(transferase isoenzyme profiles occur in rheumatoid arthritis due to)Tj
T*
(increased enzyme sialylation. \(unpublished data\).)Tj
-2.175 -1.25 Td
[(19.)-875 (Axford JS, Sumar N, )55 (Alavi )55 (A, et al. Changes in normal )]TJ
2.175 -1.25 Td
(glycosylation mechanisms in autoimmune rheumatic disease. J Clin)Tj
T*
(Invest 1992;89:1021-31.)Tj
0 Tc 30.825 42.5 Td
[(20.)-875 (W)80 (atson M, Rudd PM, Bland M, Dwek RA, )55 (Axford JS. Sugar)]TJ
-0.00011 Tc 2.175 -1.25 Td
(printing rheumatic diseases: a potential method for disease )Tj
T*
[(dif)18 (ferentiation using immunoglobulin G oligosaccharides. )55 (Arthritis)]TJ
0 Tc T*
(Rheum 1999;42:1682-90.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(21.)-875 (Frears ER, Merry )55 (AH, )55 (Axford JS. Screening neutral and acidic IgG)]TJ
2.175 -1.25 Td
(N-glycans by high density electrophoresis. Glycoconj J)Tj
0 Tc 0 Tw T*
(1999;16:283-90.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(22.)-875 (Martin K, )18 (T)70 (alukder R, Hay FC, )55 (Axford JS. Characterization of)]TJ
2.175 -1.25 Td
(changes in IgG associated oligosaccharide profiles in rheumatoid)Tj
T*
(arthritis, psoriatic arthritis, and ankylosing spondylitis using )Tj
T*
(fluorophore linked carbohydrate electrophoresis. J Rheumatol)Tj
0 Tc 0 Tw T*
(2001;28:1531-6.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(23.)-875 (Sumar N, Bodman KB, Rademacher )18 (TW)92 (, et al. )55 (Analysis of )]TJ
2.175 -1.25 Td
(glycosylation changes in IgG using lectins. J Immunol Methods)Tj
0 Tc 0 Tw T*
(1990;131:127-36.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(24.)-875 (V)111 (an den Steen PE, Proost P)111 (, Grillet B, et al: Cleavage of denatured)]TJ
2.175 -1.25 Td
(natural collagen type II by neutrophil gelatinase B reveals enzyme)Tj
T*
[(specificity)65 (, posttranslational modifications in the substrate and the)]TJ
T*
[(formation of remnant epitopes in rheumatoid arthritis. F)74 (ASEB J)]TJ
0 Tc 0 Tw T*
(2002;16:379-89.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(25.)-875 (Kieda C, Paprocka M, Krawczenko )55 (A, et al. New human )]TJ
2.175 -1.25 Td
(microvascular endothelial cell lines with tissue adhesion molecules)Tj
T*
(phenotypes. Endothelium 2002;9:247-61.)Tj
-2.175 -1.25 Td
[(26.)-875 (Almquist J, Dahlgren C, Lef)18 (fler H, Karlsson )55 (A. )55 (Activation of)]TJ
2.175 -1.25 Td
(neutrophil NADPH-oxidase by galectin-1. J Immunol)Tj
0 Tc 0 Tw T*
(2002;168:4024-41.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(27.)-875 (Cebo C, Dambrouck )18 (T)74 (, Maes E, et al. Recombinant human )]TJ
2.175 -1.25 Td
(interleukins IL-1 alpha, IL-1 beta, IL-4, IL-6, and IL-7 show)Tj
T*
[(dif)18 (ferent and specific calcium-independent carbohydrate-binding)]TJ
T*
(properties. J Biol Chem 2001;276:5685-91.)Tj
-2.175 -1.25 Td
[(28.)-875 (Petersen SV)129 (, )18 (Thiel S, Jensenius JC. )18 (The mannan-binding lectin)]TJ
2.175 -1.25 Td
(pathway of complement activation: biology and disease association.)Tj
T*
(Mol Immunol 2001;38:133-49.)Tj
-2.175 -1.25 Td
[(29.)-875 (W)80 (ong NK, Kojima M, Dobo J, )55 (Ambrus G, Sim RB. )55 (Activities of)]TJ
2.175 -1.25 Td
(the MBL-associated serine proteases \(MASPs\) and their regulation)Tj
T*
(by natural inhibitors. Mol Immunol 1999;36:853-61.)Tj
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
ET
/GS2 gs
BT
/T1_2 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
59 0 obj
<>stream
8;Z\7$$*m:%+P;AW:.)-mic1._DKJYWh#=47'*68@E<7ArYQin?amcebD?$6O)N2a
P5gkZpk0K&b@2(X4_Yd,V@;4%D_NbtYHqZ5>TW<%k5=`sHX-bf5>*nDpplECKL/-d
A;)ro:SFo+T=I]A(l$RNRSIPh_DGMD>Xfoud(]mPo!kR^*mV&Z=L6u:lYMeD8Qt5R
P02TU'DA2G8tq\<^?F@p00-EqpjC>!p"`9u>EiP?2.\6P]#%<`s.`],0(T?\%ngJn:ERaUh)G;u2JtmrID/;^Cfk.ZR
jOKAJpitWD)2+_E:sQtCl[d2a;OQV#%=O1GEl6%q@0Kf3j&K=F&`oMk/F%'uR;%Ph
"ttN'IMW!UTOp.G,FpJdSfs$V:kA#7fJg.6eG"WU?[S?o1pZZ)UpdlLc]4[WQ:,9:
XGYp6B4^mJlkeo@HbX[&ieF!FX9ORI^2DrK8bKT7G]Z-1/sK^#;0+mWF`\gR;rE7;
JqJ`Ffa7Bij3.'kojZ0-VnfQ,.6^T$NCK\jBJ^We`rAAqa01T;@/R.jc<9bJ&Uk]W
hS@_CYHnfH~>
endstream
endobj
63 0 obj
[/Indexed/DeviceRGB 255 62 0 R]
endobj
62 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
83 0 obj
<>
endobj
86 0 obj
<>
endobj
123 0 obj
<>
endobj
155 0 obj
<>
endobj
87 0 obj
<>
endobj
117 0 obj
<>stream
H|T Pg{FQfg"(.#b@9rNt8fS1 rx * 7hĬ+$7Wv_k!ݭڭ_{_pL`8N{]q&FmAK/7
l8l-bK;dKB[%Ӧ=H/kpvvqrvNٶ=^9+^xтcm<.VzFʍ)xuAZBNJgtrkPƩ
D>;U1(Cqи(sZVW+=W*CsuqJ
3$48v(atuÖ`:ۋaEvaFbW1GFg,[XGT Ղr)NS ="L(0oBĄL6iʤIbwQKsOo$r uL?r^V5BZ;[X1At9StSL=n#ɶͰ,M^)QJ8
j ]-rKėF
ՕCV(RB?sTpj
1=ͥ
mr
a&
<*!4VANhI=
Wegz,oT4 /Q<$ ^0A`gjTSe>hC:+1p+ (`LKIM SiYln"yaAFvMFĀL#&1W98f"m ;
GH0@eh;|HzL4"/>zSu(>/aH%a ey;R"VDv<.sdV# M9tBB6 d"
2}MMɺZ}YB0H 6t@H5CդX1bY+|M9b@u*4y#'#OBX<8pAl^V[XylFAȎBDF>`RT{X#.kqBH?)vIrrewpxIvg6,O9P0ToQ#HĖf7O˟mt-C7%z:;@W:sh]àIaf?W)|ʓvLܷ,ߑ߄/S-5oM;3t7go 8*ɪ>P
uoЍI
0@1Nܵ8p{Էoҿ&vgQ